Frontiers in Immunology
Cure8 research brief
Why This Matters
Eye inflammation is a common and potentially serious extraintestinal manifestation of IBD; understanding shared immune mechanisms and treatment implications can help patients and clinicians anticipate risks and coordinate care.
Who Should Pay Attention
Clinicians (gastroenterologists and ophthalmologists), researchers studying immune mechanisms and the microbiome, and adult patients with IBD who have or are at risk for eye symptoms.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This Frontiers in Immunology review frames eye involvement in IBD through a “gut–eye axis,” summarizing shared mechanisms such as circulating inflammatory cytokines, aberrant lymphocyte homing, cross‑reactive antibodies, genetic overlap, and microbiome dysbiosis that may disrupt the blood–ocular barrier.
The review reiterates that systemic anti‑TNF agents (for example, infliximab) are a mainstay for severe or refractory ocular inflammation, while gut‑selective biologics (for example, vedolizumab) may carry risks of extraintestinal exacerbation and thus require cautious use and close monitoring.
Multidisciplinary management (gastroenterology plus ophthalmology) and further research into targeted therapies and mechanistic pathways are emphasized.
Keep In Mind
This classification is based on the article abstract (structured content depth: abstract). The paper is a review synthesizing current evidence and hypotheses rather than reporting a single new trial; recommendations about therapies reflect the review’s synthesis and should be interpreted alongside clinical guidelines and individual patient circumstances.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in Immunology
AuthorsXuewei Fu, Shisi Hu
InstitutionHainan General Hospital
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedOct 26, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Systematic Review of Malignancy Risk with Biologic, Advanced Small-Molecule, and Thiopurine Therapies for Inflammatory Bowel Disease
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
Hepatic and splenic tuberculosis following infliximab therapy for refractory ulcerative colitis: a case report and literature review
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
Biologics, small molecules, and extraintestinal malignancies in inflammatory bowel disease: practical questions and evidence-based answers.
People with IBD often need long-term advanced therapies. Cancer risk concerns commonly influence treatment choices—this review compiles current evidence to help patients and clinicians weigh risks when starting or...